Catequentinib

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H22FN3O3
Molecular Weight	407.4375
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(OCC2(N)CC2)C=C3N=CC=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1

InChI

InChIKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N

InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C23H22FN3O3
Molecular Weight	407.4375
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28953502 | https://www.ncbi.nlm.nih.gov/pubmed/27716285 | https://clinicaltrials.gov/ct2/show/NCT01924195

AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Platelet-derived growth factor receptor beta 56 Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28953502 \| https://www.ncbi.nlm.nih.gov/pubmed/27716285 \| https://www.clinicaltrials.gov/ct2/show/NCT01924195	Antagonist 2778
Vascular endothelial growth factor receptor 2 104 Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28953502 \| https://www.ncbi.nlm.nih.gov/pubmed/27716285 \| https://www.clinicaltrials.gov/ct2/show/NCT01924195 \| http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=9601	Antagonist 2778	0.2 nM [IC50]
Vascular endothelial growth factor receptor 3 41 Target ID: CHEMBL1955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28953502 \| https://www.ncbi.nlm.nih.gov/pubmed/27716285 \| https://www.clinicaltrials.gov/ct2/show/NCT01924195 \| https://sage.airexmarket.com/documents/57f1b296b9ede0664300000b	Antagonist 2778	1.0 nM [IC50]
Stem cell growth factor receptor 53 Target ID: CHEMBL1936 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28953502 \| https://www.ncbi.nlm.nih.gov/pubmed/27716285 \| https://www.clinicaltrials.gov/ct2/show/NCT01924195 \|	Antagonist 2778
Fibroblast growth factor receptor 1 45 Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27716285 \| http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=9601	Antagonist 2778	7.7 null [pIC50]
Fibroblast growth factor receptor 2 25 Target ID: CHEMBL4142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27716285	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Alveolar soft part sarcoma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT03016819 http://adisinsight.springer.com/drugs/800038084	Primary	Phase III 656	Unknown Approved Use Unknown
Leiomyosarcoma 3 Sources: https://clinicaltrials.gov/ct2/show/NCT03016819 http://adisinsight.springer.com/drugs/800038084	Primary	Phase III 656	Unknown Approved Use Unknown
Synovial sarcoma 7 Sources: https://clinicaltrials.gov/ct2/show/NCT03016819 http://adisinsight.springer.com/drugs/800038084	Primary	Phase III 656	Unknown Approved Use Unknown
Soft tissue sarcoma 10 Sources: https://clinicaltrials.gov/ct2/show/NCT03016819 http://adisinsight.springer.com/drugs/800038084	Primary	Phase III 656	Unknown Approved Use Unknown
Medullary thyroid carcinoma 5 Sources: https://clinicaltrials.gov/ct2/show/NCT02586350	Primary	Phase III 656	Unknown Approved Use Unknown
Gastric cancer 53 Sources: https://clinicaltrials.gov/ct2/show/NCT02461407	Primary	Phase III 656	Unknown Approved Use Unknown
Non-small cell lung cancer 206 Sources: https://clinicaltrials.gov/ct2/show/NCT02388919	Primary	Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.	2016 Oct 4	27716285

Patents

Sample Use Guides

In Vivo Use Guide

Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)

Route of Administration: Oral

In Vitro Use Guide

AN3CA cells appeared the most sensitive to AL3818 with an IC50 value of 84 nM. The other cell lines were approximately 28- to 550-fold less sensitive to AL3818. HEC1B had an IC50 value of 46 uM, and MFE296 cells were sensitive to AL3818, with an IC50 value of 2.9 uM compared with 3.2, 28.9, 29, and 40 uM for Ishikawa, MFE280, KLE, and HEC1A, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:14:01 GMT 2023` Edited by `admin` on `Sat Dec 16 02:14:01 GMT 2023`
Record UNII	GKF8S4C432
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANLOTINIB

Preferred Name

English

Catequentinib

Official Name

English

CATEQUENTINIB [USAN]

Common Name

English

1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine

Systematic Name

English

Catequentinib [WHO-DD]

Common Name

English

ALTN

Common Name

English

AL3818

Code

English

AL-3818

Code

English

catequentinib [INN]

Common Name

English

Cyclopropanamine, 1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129825